On May 31, 2021, a gold miner tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the Cacao health center, French Guiana. He worked in a legal gold mine located 72 km from Cayenne (including 13 km of forest trail) in the Amazon Forest. Other workers from the same site were reported as symptomatic, although a large part of this specific population had benefited from complete coronavirus disease (COVID-19) vaccination in the previous month. A medical team went on site to investigate, examine, and screen the 44 employees of the mine. We describe results of the outbreak investigation.

The Study

We collected data by completing standardized forms with data gathered through interviews and medical examination of all gold miners and by reviewing the health center records. All employees of the mine were examined by a physician and screened by nasopharyngeal Panbio COVID-19 Ag Rapid Test device (Abbott Laboratories, https://www.abbott.com) if they were symptomatic; all miners underwent SARS-CoV-2 PCR EurobioPlex SARS-CoV-2 Multiplex (Eurobio Scientific, https://www.eurobio-scientific.com) testing on June 2, 2021. All employees were reassessed on June 8 and 15, 2021; those with negative results were rescreened by PCR. We performed serologic tests on blood specimens collected from 39 gold miners whether PCR was negative or positive. Serum samples were initially tested with anti–SARS-CoV-2 ELISA IgG (Euroimmun, https://www.euroimmun.com). We used descriptive statistics to analyze the variables and performed univariate analyses. Intervention was a public health response as part of activities of Cayenne Hospital. All gold miners gave their verbal informed consent for recording and processing of information during interviews and for the use of their biologic results for research purposes, and physicians completed a nonobjection form in accordance with laws of France.

Mine workers were mostly men (42/44); median age was 53.3 years. Eighteen of the workers had risk factors for severe COVID-19: high blood pressure (11/44), diabetes mellitus (4/44), or obesity (4/44). Miners lived onsite in separate rooms but shared face-to-face meals and machine cabins. They also worked outside without masks. Twenty-one workers reported contacts outside the mining site during the previous 2 weeks.

The first symptomatic cases occurred on May 29 among 3 machine operators and 1 miner. Their antigen tests and PCR results were positive on June 2. The
peak of the outbreak occurred 2 days after the early cases, on May 31 (Figure). Five asymptomatic miners who tested negative moved to a separate open housing for quarantine. Among them, 4 became symptomatic during June 6–8 and tested positive on June 8.

The overall attack rate was 54.5% (24/44); 87% were symptomatic, 65% with fever, and 22.6% with dyspnea. No clinically severe COVID-19 (I) was observed, and no patient was hospitalized. Among infected miners, 18/23 (78.2%) had a cycle threshold (Ct) <28 (Appendix Table 1, https://wwwnc.cdc.gov/EID/article/27/10/21-1427-App1.pdf). The variant of concern (VOC) gamma (P.1 lineage), also known as 20J/501Y.V3, was identified in 9/9 viruses sequenced by the Pasteur Institute (Appendix Table 2), without any new mutation. Of the 4 persons who tested negative and were not vaccinated, 3 had a positive SARS-CoV-2 IgG. Patient 40 could be the index case-patient; he reported visiting his family the previous week and had an asymptomatic SARS-CoV-2 infection with Ct of 33–35.

Regarding immune status, 25/44 (56.8%) were fully vaccinated with BNT162b2 vaccine (Pfizer-BioNTech, https://www.pfizer.com); 3/6 workers who had a history of COVID-19 were vaccinated with a single injection, according to the guidelines of France (2) (Table). Several BNT162b2 batch numbers were involved. Vaccine temperature had been monitored and electronically recorded by LogTag Analyzer (LogTag Recorders, http://www.logtag-recorders.com) without any break in the cold chain. The attack rate was 15/25 (60.0%) in fully vaccinated miners, 6/15 (40.0%) in those partially vaccinated or with a history of COVID-19, and 3/4 (75%) in those not vaccinated. Attack rate was 0/6 among persons with a previous history of COVID-19 versus 63.2% among those with no previous history (Table). No other factors were found to be associated with the risk for infection.

Among the mine workers were recorded 14/28 vaccine clinical failures (COVID-19 onset >14 days after the second dose, or after a single dose for patients with history of COVID-19); none had serious infections. Twelve (42.3%) of the 28 fully vaccinated reported vaccine reactogenicity. Among the fully vaccinated, the SARS-CoV-2 IgG ratio was high for most (mean 9.22, SD 1.5). We performed serologic testing a median of 4 (interquartile range [IQR] 2–5.5) days after the onset of symptoms in symptomatic patients and 58 (IQR 46–62) days after vaccination.

mRNA vaccines such as BNT162b2 demonstrated high effectiveness both in clinical trials and in real-world situations against wild-type SARS-CoV-2 and its Alpha variant infections (3,4). However, other VOC, such as Beta or Gamma, harbor mutations conferring potential escape from humoral response induced either by prior infection or vaccination, as proven by both decreased seroneutralization in vitro (5–7) and in vivo by observational studies in the case of the Beta variant (8,9). However, such breakthrough infections, even those caused by Beta variant, remain rare in fully vaccinated populations and are mostly asymptomatic or moderately symptomatic (8–10).

**Conclusions**

We describe a COVID-19 Gamma variant cluster with a high attack rate even in fully vaccinated persons. The Gamma variant is the predominant variant in French Guiana which, as of July 2021, caused a third epidemic wave, threatening to overwhelm the hospital capacity (11). Such a low vaccine efficiency against infection by the Gamma variant was not expected because in vitro studies have shown a similar reduction of neutralization for Beta or Gamma variants by BNT162b2-elicited antibodies (5) and a conserved CD4+ T-cell response against spike proteins.
Breakthrough Infections of SARS-CoV-2 Gamma Variant

from the Beta variant (6). Of the 10,262 COVID-19 vaccine breakthrough infections identified in the United States during January–April 2021, for which 555 had available sequencing, only 28 were caused by the Gamma variant (12). Furthermore, real-world effectiveness against any infection by a Beta variant, which shares a similar E484K mutation on the gene coding for the spike protein, was estimated at 75.0% (9). Given the surprisingly high attack rate, we hypothesized potential dysfunctions of conservation or administration of vaccines, but the absence of traceable cold-chain interruption and the use of different batches seemed to refute this hypothesis. The relative isolation of the mining site and careful contact tracing suggested limited numbers of viral introductions inside this community. The low C_t of positive PCR for SARS-CoV-2 despite prior vaccination suggested that a complete vaccination scheme with BNT162b2 vaccine was not sufficient to prevent symptomatic SARS-CoV-2 infection and its transmission in this context of communal life without masks. The working conditions of some miners (heat, humidity, aerosol) and the sharing of machine cabs for others could also have contributed to transmission. The absence of severe COVID-19 in a high-risk population (13) suggests but does not prove protection against severe disease, as reported for the Beta variant in another context (14).

In conclusion, we describe a VOC Gamma COVID-19 outbreak with a strikingly high attack rate among persons fully vaccinated with BNT162b2 vaccine. Our observation suggested that BNT162b2 protected from severe COVID-19. However, this single

| Characteristic | Total, no. (%) | Acute SARS-CoV-2 infection |
|---------------|---------------|-----------------------------|
| All participants | 44 | 20 | 24 |
| Mean age | 44 | 51.9 | 54.5 |
| Immune status | 25 (56.8) | 15 | 60.0 |
| History of COVID-19 | 3 (6.8) | 66.7 |
| History of COVID-19, not vaccinated | 3 (6.8) | 0.00 |
| Neither vaccinated nor history | 4 (9.1) | 3 | 75.0 |
| History of previous COVID-19 | 6 (8.9) | 6 | 0.00 |
| Sex | 38 (86.4) | 14 | 63.2 |
| Age, y | 24 (54.5) | 11 | 52.2 |
| Country of birth | 20 (45.4) | 9 | 57.1 |
| Occupation | 20 (45.4) | 8 | 60.0 |
| Eat alone | 7 (15.9) | 5 | 28.6 |
| Live alone | 37 (84.1) | 15 | 59.5 |
| Contact outside the mine in the previous 2 weeks | 26 (60.5) | 10 | 61.5 |
| Underlying conditions | 17 (39.5) | 9 | 47.1 |

*We defined acute SARS-CoV-2 infection in participants as having a positive SARS-CoV-2 antigenic or PCR test in June 2021, symptomatic or not. Of the 24 with acute infection, 21 were symptomatic and 3 asymptomatic infections. p value indicates degree of significance. COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
unexpected outbreak in a small and isolated vaccinated population requires further real-life studies on BNT162b2 vaccine effectiveness against the VOC Gamma. Masking and social distancing, even among those fully vaccinated, may be necessary among persons with frequent exposure in Gamma variant–endemic zones.

Acknowledgments
We acknowledge the contribution of Julien Tedi, Flore Lapauw, and Laura Verger; the Regional Health Agency of French Guiana (Agence régionale de la Santé de Guyane); the Public Health Agency in French Guiana (Santé Publique France Guyane); the logistics of the de-localized prevention and care centers (CDPS); Sébastien Teissier and his team; the CDPS team of Cacao and Regina, especially Malika Miguel and Solenn Ferelloc; the coordinators of CDPS; the directors of Cayenne Hospital; the laboratory team of Cayenne Hospital; and the Pasteur Institute of French Guiana. Moreover, we thank the mine manager and all his employees for their help in the investigation of this cluster.

About the Authors
Dr. Vignier is a public health and infectious disease physician in the Department of Research, Innovation and Public Health (Centre Investigation Clinique Antilles Guyane) and Infectious Disease Department of the Cayenne Hospital in French Guiana. His primary research interests include tropical disease and skin infections. Dr. Bérot is a dermatology and infectious disease physician in the Infectious Disease Department of the Ouest Guyanais Hospital in French Guiana. His primary research interests include tropical disease and skin infections.

References
1. National Institutes of Health COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2021 [cited 2021 Jun 18]. https://www.covid19treatmentguidelines.nih.gov
2. Haute Autorité de Santé. Vaccination strategy against SARS-CoV-2: vaccination of people with a history of Covid-19 [in French]. 2021 Feb 11 [cited 2021 Jun 28]. https://www.has-sante.fr/upload/docs/application/pdf/2021-02/strategie_de_vaccination_contre_le_sars-cov-2__vaccination_des_personnes_ayant_un_antecedent_de_covid-19__-_synthese.pdf
3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurttman A, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–15. https://doi.org/10.1056/NEJMoa2034577
4. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalizations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–29. https://doi.org/10.1016/S0140-6736(21)00947-8
5. Hoffmann M, Arora P, Groß R, Seidel A, Hörmich BF, Hahn AS, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184:2384–2393.e12. https://doi.org/10.1016/j.cell.2021.03.036
6. Geers D, Shamier MC, Bogers S, den Hartog G, Gomers L, Nieuwkoop NN, et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci Immunol. 2021 May 25;6:eabj1750.
7. Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021;384:1466–8. https://doi.org/10.1056/NEJMci2102017
8. Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021 Jun 14 [Epub ahead of print].
9. Abu-Raddad LJ, Chemaillhey H, Butt AA; National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021 May 5 [Epub ahead of print]. https://doi.org/10.1056/NEJMci2104974
10. Swift MD, Breeher LE, Tande AJ, Tommaso CP, Hainy CM, Chu H, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clin Infect Dis 2021 Apr 26 [Epub ahead of print]. https://doi.org/10.1093/cid/ciaa361
11. Santé Publique France. Regional epidemiological point: special COVID-19 [in French]. 2021 Jun 17 [cited 2021 Jun 18]. https://www.guyane.ars.sante.fr/system/files/2021-06/SARS_COVID-19_-_synthese.pdf
12. CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 vaccine breakthrough infections reported to CDC – United States, January 1–April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:792–3.
13. Gao YD, Ding M, Dong X, Zhang J, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76:428–55. https://doi.org/10.1111/all.14657
14. Bailly B, Guipilin P, Bouiller K, Chirouze C, N’Debi M, Soulair, et al. BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity. Clin Infect Dis. 2021 May 16 [Epub ahead of print]. https://doi.org/10.1093/cid/ciab446

Address for correspondence: Nicolas Vignier, Centre d’Investigation Clinique Antilles Guyane Inserm 1424, Centre hospitalier de Cayenne, Av. des flamboyants, BP 6006, 97306 Cayenne CEDEX, French Guiana; email: dr.vignier@gmail.com
Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021

Appendix

Nine confirmed samples of SARS-CoV-2 were submitted to whole-genome sequencing. Viral RNA was extracted from 150µL of nasal swabs using the QIAamp viral RNA Mini Kit (QIAGEN, https://www.qiagen.com) following the manufacturer’s instructions. Extracted RNAs were subjected to whole-genome sequencing following the ARTIC network protocol version 3 (https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye).

In brief, the LunaScript RT SuperMix Kit (New England Biolabs, https://www.neb.com) was used to obtain single-strand cDNA for each sample. All cDNAs were amplified using the ARTIC network SARS-CoV-2 protocol with V3 primers. Prior to library preparation, the multiplex primer sets (divided into 2 separate pools) were mixed. Sequencing was carried out on the Oxford Nanopore MinION devices (DNA Links, https://www.dnalinkseqlab.com; Oxford Nanopore Technologies, https://nanoporetech.com), utilizing FLO-MIN106 flow cells and the SQL-LSK109 ligation sequencing kit (Oxford Nanopore Technologies). On the MinION device, barcoding was carried out with the EXP-NBD104 barcoding kit (Oxford Nanopore Technologies). Nanopore sequencing reads were basecalled with Guppy 3.4.5+fb1fbb (Oxford Nanopore Technologies) and analyzed with the Nanopolish workflow provided by Artic (https://github.com/artic-network/artic-ncov2019.git, commit ddfb2dc87a4f442f821787ef90a92625f6bd6a09).

The sequences have been deposited on the GISAID website (https://www.gisaid.org).
### Appendix Table 1. Data from analysis of coronavirus disease outbreak in a legal gold mine, French Guiana, June 2021*

| No. | Date       | Result       | PCR technique | C_{\text{t}} (RdRp1) | C_{\text{t}} (RdRp2) | C_{\text{t}} (N gene) | Immune status | Symptomatic | Sequencing |
|-----|------------|--------------|---------------|----------------------|----------------------|------------------------|----------------|-------------|------------|
| 1   | 2021 Jun 2 | PCR positive | Eurobio       | 29                   | 28                   | 34                     | Non-immune     | 0           | Not done   |
| 2   | 2021 Jun 2 | 0            | Eurobio       | 29                   | 28                   | 34                     | Vaccinated 1 dose | 0           | Not done   |
| 3   | 2021 Jun 2 | PCR positive | Qiastat†      | NA                   | NA                   | 26,1                   | Vaccinated 2 doses | 1           | Gamma      |
| 4   | 2021 Jun 2 | PCR positive | Eurobio       | 19                   | 20                   | 25                     | Vaccinated 1 dose | 1           | Gamma      |
| 5   | 2021 Jun 2 | PCR positive | Eurobio       | 22                   | 21                   | 27                     | Vaccinated 2 doses | 1           | Gamma      |
| 6   | 2021 Jun 2 | 0            | Eurobio       | 21                   | 20                   | 26                     | Vaccinated 2 doses | 0           | Gamma      |
| 7   | 2021 Jun 2 | 0            | Eurobio       | 21                   | 20                   | 26                     | History of COVID-19 | 1           |            |
| 8   | 2021 Jun 2 | PCR positive | Eurobio       | 18                   | 18                   | 22                     | Vaccinated 2 doses | 1           | Gamma      |
| 9   | 2021 Jun 2 | 0            | Eurobio       | 18                   | 18                   | 22                     | History of COVID-19 | 1           |            |
| 10  | 2021 Jun 2 | PCR positive | Eurobio       | 25                   | 24                   | 29                     | Vaccinated 2 doses | 1           | Gamma      |
| 11  | 2021 Jun 2 | 0            | Eurobio       | 25                   | 25                   | 30                     | History of COVID-19 – Vaccinated 1 dose | 1           |            |
| 12  | 2021 Jun 2 | 0            | Eurobio       | 25                   | 25                   | 30                     | Vaccinated 1 dose | 1           | Not done   |
| 13  | 2021 Jun 2 | PCR positive | Eurobio       | 28                   | 27                   | 32                     | Vaccinated 2 doses | 1           | Not done   |
| 14  | 2021 Jun 2 | 0            | Eurobio       | 28                   | 27                   | 32                     | Vaccinated 2 doses | 1           | Not done   |
| 15  | 2021 Jun 2 | PCR positive | Eurobio       | 18                   | 18                   | 23                     | Vaccinated 1 dose | 1           | Not done   |
| 16  | 2021 Jun 2 | 0            | Eurobio       | 18                   | 18                   | 23                     | Vaccinated 1 dose | 1           | Not done   |
| 17  | 2021 Jun 2 | 0            | Eurobio       | 18                   | 18                   | 23                     | Non-immune     | 0           |            |
| 18  | 2021 Jun 2 | 0            | Eurobio       | 18                   | 18                   | 23                     | Vaccinated 2 doses | 1           |            |
| 19  | 2021 Jun 2 | 0            | Eurobio       | 18                   | 18                   | 23                     | History of COVID-19 | 1           |            |
| 20  | 2021 Jun 2 | PCR positive | Eurobio       | 20                   | 21                   | 26                     | Vaccinated 2 doses | 1           | Not done   |
| 21  | 2021 Jun 2 | PCR positive | Eurobio       | 20                   | 21                   | 26                     | Vaccinated 2 doses | 1           | Not done   |
| 22  | 2021 Jun 2 | PCR positive | Eurobio       | 20                   | 21                   | 26                     | Vaccinated 2 doses | 1           | Not done   |
| 23  | 2021 Jun 2 | 0            | Eurobio       | 20                   | 21                   | 26                     | History of COVID-19 | 1           |            |
| 24  | 2021 Jun 2 | PCR positive | Eurobio       | 24                   | 23                   | 28                     | Vaccinated 1 dose | 1           | Gamma      |
| 25  | 2021 Jun 2 | PCR positive | Eurobio       | 25                   | 23                   | 25                     | Vaccinated 2 doses | 1           | Gamma      |
| 26  | 2021 Jun 2 | PCR positive | Eurobio       | >36                   | NA                   | 30                     | Non-immune     | 1           | Not done   |
| 27  | 2021 Jun 2 | PCR positive | Eurobio       | >36                   | NA                   | 30                     | Vaccinated 1 dose | 1           | Not done   |
| 28  | 2021 Jun 2 | 0            | Eurobio       | >36                   | NA                   | 30                     | Vaccinated 2 doses | 0           |            |
| 29  | 2021 Jun 2 | 0            | Eurobio       | >36                   | NA                   | 30                     | Vaccinated 2 doses | 0           |            |
| 30  | 2021 Jun 2 | PCR positive | Eurobio       | 18                   | 20                   | 26                     | Vaccinated 1 dose | 1           | Not done   |
| 31  | 2021 Jun 2 | PCR positive | Eurobio       | 18                   | 20                   | 26                     | Vaccinated 1 dose | 1           | Not done   |
| 32  | 2021 Jun 2 | 0            | Eurobio       | 18                   | 20                   | 26                     | Vaccinated 1 dose | 0           |            |
CT values were not different according to the immune status: median (interquartile range [IQR]) of Ct(RdRp1) = 29 (25-35) for non-immune (n = 3), 21.5 (18-25) for vaccinated 1 dose (n=6) and 23 [21-27] for vaccinated 2 doses (n = 13), p = 0.15 with median test. For RdRp1: median [IQR] = 28 [25-33] for non-immune (n = 3), 20 [20-23] for vaccinated 1 dose (n = 5) and 23 (21-26) for vaccinated 2 doses (n = 13), p = 0.09 with median test. For N gene: median (IQR) = 32 (30-34) for non-immune (n = 2), 26 (25-28) for vaccinated 1 dose (n = 5), and 27 (26-31) for vaccinated 2 doses (n = 14), p = 0.30 with median test.

*PCR was performed with QIAstat-Dx respiratory panel for this patient. Only SARS-CoV-2 was detected.

Appendix Table 2. Sequencing data for 9 SARS-CoV-2 viruses from an outbreak in workers in a legal gold mine, Cacao, French Guiana, June 2021

| GISAID accession ID | Collection date | Location | Host | Sex | Age | Last vaccinated | Passage | Specimen | Lineage | Clade | No. |
|---------------------|-----------------|----------|------|-----|-----|----------------|---------|----------|---------|-------|-----|
| EPI_ISL_2627852     | 2021 Jun 2      | South America / French Guiana / Cacao | Human | M | 53 | 2 doses Pfizer | Original | Nasopharyngeal swab | P.1 | GR | 3 |
| EPI_ISL_2627854     | 2021 Jun 2      | South America / French Guiana / Cacao | Human | M | 42 | 1st dose Pfizer 2021 May 5 | Original | Nasopharyngeal swab | P.1 | GR | 25 |
| EPI_ISL_2627855     | 2021 Jun 2      | South America / French Guiana / Cacao | Human | M | 63 | 2nd dose Pfizer 2021 Apr 7 | Original | Nasopharyngeal swab | P.1 | GR | 10 |
| EPI_ISL_2627856     | 2021 Jun 2      | South America / French Guiana / Cacao | Human | M | 58 | 2nd dose Pfizer 2021 May | Original | Nasopharyngeal swab | P.1 | GR | 5 |
| EPI_ISL_2627857     | 2021 Jun 2      | South America / French Guiana / Cacao | Human | M | 59 | 2nd dose Pfizer 2021 Apr 7 | Original | Nasopharyngeal swab | P.1 | GR | 8 |
| EPI_ISL_2627858     | 2021 Jun 2      | South America / French Guiana / Cacao | Human | M | 53 | 2nd dose Pfizer 2021 Apr 7 | Original | Nasopharyngeal swab | P.1 | GR | 11 |
| GISAID accession ID | Collection date | Location                          | Host  | Sex | Age | Last vaccinated        | Passage | Specimen                  | Lineage | Clade | No. |
|---------------------|-----------------|-----------------------------------|-------|-----|-----|-------------------------|---------|---------------------------|---------|-------|-----|
| EPI_ISL_2627859     | 2021 Jun 2      | South America / French Guiana / Cacao | Human | M   | 51  | 2nd dose Pfizer 2021 Apr 7 | Original | Nasopharyngeal swab       | P.1     | GR    | 22  |
| EPI_ISL_2629233     | 2021 Jun 8      | South America / French Guiana / Cacao | Human | M   | 51  |                              | Original | Nasopharyngeal swab       | P.1     | GR    | 24  |
| EPI_ISL_2629234     | 2021 Jun 8      | South America / French Guiana / Cacao | Human | M   | 49  |                              | Original | Nasopharyngeal swab       | P.1     | GR    | 4   |